Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

F. Vescini, R. Attanasio, A. Balestrieri, F. Bandeira, S. Bonadonna, V. Camozzi, S. Cassibba, R. Cesareo, I. Chiodini, C. Maria Francucci, L. Gianotti, F. Grimaldi, R. Guglielmi, B. Madeo, C. Marcocci, A. Palermo, A. Scillitani, E. Vignali, V. Rochira, M. Zini

Research output: Contribution to journalArticlepeer-review


Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.

Original languageEnglish
Pages (from-to)807-834
Number of pages28
JournalJournal of Endocrinological Investigation
Issue number7
Publication statusPublished - Jul 1 2016


  • Adherence
  • Androgen deprivation
  • Aromatase inhibitors
  • Bisphosphonates
  • Denosumab
  • Drug-induced osteoporosis
  • Fracture
  • Length of therapy
  • Male osteoporosis
  • Non-responder
  • Osteoporosis
  • SERMs
  • Side effects
  • Strontium ranelate
  • Teriparatide
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis'. Together they form a unique fingerprint.

Cite this